

RAC/M/52B-2/2020

Final

8 October 2020

**Minutes of the 52B-part 2 Meeting
of the Committee for Risk Assessment
(RAC-52B-2)**

Tuesday 6 October, 14.00 to Thursday 8 October, 17.30

Summary Record of the Proceedings, and Conclusions and action points

Chair's opening address

The Chair, Tim Bowmer, reflected on the following topic in his opening address:

The RAC-52B meeting planned for the week of 16 to 20 March 2020 was cancelled at short notice due to Covid-19-related reasons outside the control of ECHA. The action taken by the RAC Secretariat in response was to reschedule the 13 affected dossiers for separate meetings later in the year, namely three dossiers on 3 May and the remaining 10 to this meeting on 6 to 8 October 2020. In this way, the agendas under preparation for RAC-53 in June and RAC-54 in September could be scheduled and completed as planned without disruption.

The procedural time-limits (taken as 18 months from the date on which a dossier was declared in conformity) were exceeded in 9 of the 13 cases. Through the rescheduled meetings, opinions on all 13 cases have been adopted by RAC. These are in the process of being completed to send to the Commission and publish on the ECHA website; no further actions are thus anticipated.

He informed the Committee that the Deputy Chair Johanna Peltola-Thies would chair sections of RAC-54.

Agenda point	
Conclusions / agreements / adoptions	Action requested after the meeting (by whom/by when)
2. Adoption of the Agenda	
The Agenda (RAC/A/52B-2/2020) was adopted with one addition under AOB.	SECR to upload the adopted Agenda to the RAC CIRCABC and to the ECHA website as part of the RAC-52B Part 2 minutes.
4. Appointment of (co-)rapporteurs	
a) Appointment of (co-)rapporteurs for CLH dossiers The Secretariat collected the names of volunteers for rapporteurships for CLH dossiers, as listed in the restricted document in the Interact collaboration tool. The Committee agreed upon the proposed appointments of the Rapporteurs for the intentions and/or newly submitted CLH dossiers,	-

5. Harmonised classification and labelling (CLH)

5.1 CLH dossiers

A. Substances with hazard classes for agreement by A-listing following the usual scrutiny but without plenary debate

- 1) Isoflucypram: physical hazards, acute toxicity, STOT SE, skin corrosion/ irritation, serious eye damage/eye irritation, respiratory and skin sensitisation, germ cell mutagenicity, aspiration hazards, hazards to the aquatic environment
- 2) Ammonium bromide: acute toxicity (dermal and oral), serious eye damage/eye irritation, skin corrosion/irritation, skin sensitisation, germ cell mutagenicity, carcinogenicity
- 3) Dimoxystrobin (ISO): acute toxicity, skin corrosion/irritation, serious eye damage/eye irritation, skin sensitisation, hazards to the aquatic environment
- 4) 2,4,6-tri-tert-butylphenol: acute toxicity (oral, dermal), skin corrosion/irritation, serious eye damage/eye irritation, skin sensitisation, germ cell mutagenicity, carcinogenicity, STOT SE
- 5) Sodium pyrithione: physical hazards, skin corrosion/irritation, serious eye damage/eye irritation, STOT SE, germ cell mutagenicity, carcinogenicity, hazards to the aquatic environment
- 6) Pendimethalin (ISO): hazards to the aquatic environment
- 7) Pyridalyl (ISO): physical hazards (except explosives and self-reactive substance), acute toxicity, skin corrosion/irritation, serious eye damage/eye irritation, skin sensitisation, germ cell mutagenicity, carcinogenicity, STOT SE, STOT RE, hazards to the aquatic environment

B. Substances with hazard classes for agreement in plenary session

- 1) isoflucypram
- 2) ammonium bromide
- 3) dimoxystrobin (ISO)
- 4) diethylene glycol monomethyl ether
- 5) 2,4,6-tri-tert-butylphenol
- 6) sodium pyrithione
- 7) bisphenol A
- 8) pendimethalin (ISO)
- 9) pyridalyl (ISO)
- 10) methyl methacrylate

1. Isoflucypram

The Chair welcomed the expert accompanying the ECPA Regular Stakeholder Observer and informed that isoflucypram is an active substance in plant protection products used as a fungicide. It has no existing entry in Annex VI to the CLP Regulation. Legal deadline for the adoption of an opinion was 3 October 2020.

The DS (UK) proposes to classify the substance as Acute Tox. 4; H332 (ATE=2.2 mg/l (dust or mist), Skin Sens. 1B; H317, Aquatic Acute 1; H400 (M=10) and Aquatic Chronic 1; H410 (M=1).

Selected physical hazards (explosive, flammable solid, self-reactive substance, pyrophoric solid, self-heating substance, substance which in contact with water emits flammable gas, oxidising solid, organic peroxide), acute toxicity, skin corrosion/irritation, serious eye damage/eye irritation, respiratory sensitisation, skin sensitisation, germ cell mutagenicity, carcinogenicity, toxicity to reproduction, STOT SE, STOT RE, aspiration hazard, hazards to the aquatic environment and hazardous to the ozone layer were open for comments during the Consultation.

RAC adopted by consensus the opinion with a proposal for the harmonised classification and labelling as indicated in Table 1 below.

[Acute Tox. 4; H332 (ATE=2.2 mg/l (dust or mist), Skin Sens. 1B; H317, Repr. 2; H361f, Aquatic Acute 1; H400 (M=10), Aquatic Chronic 1; H410 (M=1)]

RAC agreed on no classification for physical hazards, acute oral and dermal toxicity, skin/eye irritation, respiratory sensitisation, STOT SE, germ cell mutagenicity, aspiration hazards and hazards to the Ozone layer.

RAC agreed on no classification for STOT RE, carcinogenicity (due to inconclusive data), developmental toxicity and for effects on or via lactation.

Rapporteurs to revise the opinion in accordance with the discussion in RAC and to provide it to SECR.

SECR to make an editorial check of the opinion documents in consultation with the Rapporteurs.

SECR to forward the adopted opinion and its annexes to COM and publish it on the ECHA website.

The expert accompanying the ECPA Stakeholder Observer commented on STOT RE, fertility and sexual function and developmental toxicity.

2. Ammonium bromide

The Chair welcomed the Dossier Submitter representative, the expert accompanying the Cefic Regular Stakeholder Observer and an Occasional Stakeholder Observer (ECETOC). He informed that ammonium bromide is an industrial chemical used as a flame retardant and as a precursor for biocidal active substances. It has no current Annex VI entry. The legal deadline for the adoption of an opinion was 23 August 2020.

The DS (SE) proposes to classify the substance as Eye Irrit. 2; H319, Repr. 1B; H360FD, Lact.; H362, STOT SE 3; H336, STOT RE 2; H373 (nervous system, thyroid).

Acute toxicity, skin corrosion/irritation, serious eye damage/eye irritation, skin sensitisation, carcinogenicity, germ cell mutagenicity, reproductive toxicity, STOT SE and STOT RE were open for comments during the Consultation.

RAC adopted by consensus the opinion with a proposal for the harmonised classification and labelling as indicated in Table 1 below.

[Eye Irrit. 2; H319, Repr. 1B; H360FD, Lact.; H362, STOT SE 3; H336, STOT RE1; H372 (nervous system)]

RAC agreed on no classification for acute oral, dermal and inhalation toxicity, skin corrosion/irritation, skin sensitisation, germ cell mutagenicity and carcinogenicity.

Rapporteurs to revise the opinion in accordance with the discussion in RAC and to provide it to SECR.

SECR to make an editorial check of the opinion documents in consultation with the Rapporteurs.

SECR to forward the adopted opinion and its annexes to COM and publish it on the ECHA website.

The expert accompanying the Cefic Stakeholder Observer commented on acute inhalation toxicity, STOT SE, STOT RE, fertility and sexual function, developmental toxicity and on lactation.

3. Dimoxystrobin (ISO)

The Chair welcomed the expert accompanying the ECPA Regular Stakeholder Observer. He informed that dimoxystrobin (ISO) is an active substance in plant protection products used as a fungicide. It has an existing Annex VI entry as Acute Tox. 4*; H332, Carc. 2; H351, Repr. 2; H361d***, Aquatic Acute 1; H400 and Aquatic Chronic 1; H410. The legal deadline for the adoption of an opinion is 5 November 2020.

The DS (HU) proposes to add Lact.; H362, STOT RE 2; H373 (blood) and M-factors for hazards to the aquatic environment (M=100 for both acute and chronic aquatic hazard), to confirm Acute Tox. 4; H332 (ATE (inhalation)=1.3 mg/l (dust or mist)) and to remove classification for reproductive toxicity.

Acute toxicity, skin corrosion/irritation, serious eye damage/eye irritation, skin sensitisation, reproductive toxicity, STOT RE and hazardous to the aquatic environment were open for comments during the Consultation.

RAC adopted by consensus the opinion with a proposal for the harmonised classification and labelling as indicated in Table 1 below.

[Acute Tox. 4; H332 (ATE=1.3 mg/l (dust or mist), Repr. 2; H361d, Aquatic Acute 1; H400 (M=100), Aquatic Chronic 1; H410 (M=100)]

RAC agreed on no classification for acute oral and dermal toxicity, skin corrosion/irritation, serious eye damage/eye irritation and skin sensitisation.

RAC agreed on no classification for STOT RE, fertility and sexual function and for effects on or via lactation.

Rapporteurs to revise the opinion in accordance with the discussion in RAC and to provide it to SECR.

SECR to make an editorial check of the opinion documents in consultation with the Rapporteurs.

SECR to forward the adopted opinion and its annexes to COM and publish it on the ECHA website.

The expert accompanying the ECPA Stakeholder Observer commented on reproductive toxicity.

4. Diethylene glycol monomethyl ether

The Deputy Chair welcomed the expert accompanying the Cefic Regular Stakeholder Observer. She informed that DGME is an industrial chemical primarily used as an intermediate or industrial processing aid and an additive in aviation fuels. It has an existing entry in Annex VI to the CLP Regulation as Repr. 2; H361d***. The legal deadline for the adoption of an opinion was 3 October 2020.

The DS (NL) proposes to change the classification to Repr. 1B; H360D.

Reproductive toxicity was the only hazard class open for comments during the Consultation.

RAC adopted by consensus the opinion with a proposal for the harmonised classification and labelling as indicated in Table 1 below.

[Repr. 1B; H360D, SCL = 3%]

RAC agreed on no classification for fertility and sexual function and for effects on or via lactation.

Rapporteurs to revise the opinion in accordance with the discussion in RAC and to provide it to SECR.

SECR to make an editorial check of the opinion documents in consultation with the Rapporteurs.

SECR to forward the adopted opinion and its annexes to COM and publish it on the ECHA website.

The expert accompanying the Cefic Stakeholder Observer commented on developmental toxicity.

5. 2,4,6-tri-tert-butylphenol

The Deputy Chair informed that 2,4,6-tri-tert-butylphenol is an industrial chemical used in indoor (e.g. cooling liquids in refrigerators, oil-based electric heaters) and outdoor closed systems (e.g. hydraulic liquids in automotive suspension, lubricants in motor oil and break fluids). It has no existing entry in Annex VI to the CLP Regulation. The legal deadline for the adoption of an opinion was 15 August 2020.

The DS (BE) proposes to classify the substance as Acute Tox. 4; H302 (ATE = 500 mg/kg bw), Skin Sens. 1B; H317, Repr. 2; H361d and STOT RE 2; H373 (liver).

Acute oral and dermal toxicity, skin corrosion/irritation, serious eye damage/eye irritation, skin sensitisation, germ cell mutagenicity, carcinogenicity, reproductive toxicity, STOT SE and STOT RE were open for comments during the Consultation.

RAC adopted by consensus the opinion with a proposal for the harmonised classification and labelling as indicated in Table 1 below.

[Acute Tox. 4; H302 (ATE=500 mg/kg bw), Skin Sens. 1B; H317, Repr. 1B; H360D, STOT RE 2; H373 (liver)]

RAC agreed on no classification for acute dermal toxicity, skin corrosion/irritation, serious eye damage/eye irritation, germ cell mutagenicity, carcinogenicity, STOT SE, fertility and for effects on or via lactation.

Rapporteur to revise the opinion in accordance with the discussion in RAC and to provide it to SECR.

SECR to make an editorial check of the opinion documents in consultation with the Rapporteur.

SECR to forward the adopted opinion and its annexes to COM and publish it on the ECHA website.

6. sodium pyrithione

The Chair welcomed two experts accompanying the Cefic and the ECPA Regular Stakeholder Observers. He informed that sodium pyrithione is an active substance in biocidal products used against bacteria, moulds, yeast, actinomycetes. It has no current Annex VI entry. The legal deadline for the adoption of an opinion was 13 September 2020.

The DS (SE) proposes to classify the substance as Acute Tox. 4; H302 (ATE=500 mg/kg bw), Acute Tox. 4; H312 (ATE=1800 mg/kg bw), Acute Tox. 3; H331, (ATE=0.5 mg/l (dust or mist)), Skin Irrit. 2; H315, Eye Irrit. 2; H319, Skin Sens. 1; H317, STOT RE 1; H372, Aquatic Acute 1; H400, M=100 and Aquatic Chronic 2; H411.

Selected physical hazards (explosive, flammable solid, self-reactive substance or mixture, pyrophoric solid, self-heating substance or mixture, substance or mixture which in contact with water emits flammable gas, oxidising solid, substance or mixture corrosive to metals), acute toxicity, skin corrosion/irritation, serious eye damage/eye irritation, skin sensitisation, germ cell mutagenicity, carcinogenicity, toxicity to reproduction, STOT SE, STOT RE and hazards to the aquatic environment were open for comments during the Consultation.

RAC adopted by consensus the opinion with a proposal for the harmonised classification and labelling as indicated in Table 1 below.

[Acute Tox. 4; H302 (ATE=500 mg/kg bw), Acute Tox. 3; H311 (ATE=790 mg/kg bw), Acute Tox. 3; H331 (ATE=0.5 mg/l (dust or mist), Skin Irrit. 2; H315, Eye Irrit. 2; H319, Skin Sens. 1; H317, STOT RE 1; H372 (nervous system), Aquatic Acute 1; H400 (M=100), Aquatic Chronic 2; H411, EUH070]

RAC agreed on no classification for physical hazards, STOT SE, germ cell mutagenicity, carcinogenicity, reproductive toxicity and for effects on or via lactation.

Rapporteurs to revise the opinion in accordance with the discussion in RAC and to provide it to SECR.

SECR to make an editorial check of the opinion documents in consultation with the Rapporteurs.

SECR to forward the adopted opinion and its annexes to COM and publish it on the ECHA website.

The expert accompanying the Cefic Stakeholder Observer commented on acute toxicity, STOT RE and reproductive toxicity. The expert accompanying the ECPA Stakeholder Observer commented on acute toxicity and skin sensitisation.

7. bisphenol A

The Deputy Chair welcomed the Dossier Submitter representatives, three Occasional Stakeholder Observers, the expert accompanying the Cefic Regular Stakeholder Observer and the expert accompanying the Occasional Stakeholder Observer from Plastics Europe. She informed that bisphenol A is an industrial chemical used for the manufacture of plastic products, chemicals and epoxy resins. It has an existing entry in Annex VI to the CLP Regulation for the following human health hazards: Repr. 1B; H360F, STOT SE 3; H335, Eye Dam. 1; H318, Skin Sens. 1; H317. The legal deadline for the adoption of an opinion is 17 October 2020.

The DS (DE) proposes to add classification for hazards to the aquatic environment: Aquatic Acute 1; H400 (M=1) and Aquatic Chronic 1; H410 (M=10).

Hazards to the aquatic environment were open for comments during the Consultation.

RAC adopted by consensus the opinion with a proposal for the harmonised classification and labelling as indicated in Table 1 below.

[Aquatic Acute 1; H400 (M=1), Aquatic Chronic 1; H410 (M=10)]

Rapporteurs to revise the opinion in accordance with the discussion in RAC and to provide it to SECR.

SECR to make an editorial check of the opinion documents in consultation with the Rapporteurs.

SECR to forward the adopted opinion and its annexes to COM and publish it on the ECHA website.

The expert accompanying the Cefic Stakeholder Observer and the EUPC Occasional Stakeholder Observer commented on aquatic chronic toxicity.

8. Pendimethalin (ISO)

The Deputy Chair welcomed the Dossier Submitter representative and the expert accompanying the ECPA Regular Stakeholder Observer. She informed that pendimethalin (ISO) is used as a herbicide. It has an existing entry in Annex VI as Skin Sens. 1; H317, Aquatic Acute 1; H400 and Aquatic Chronic 1; H410. The legal deadline for the adoption of an opinion was 9 August 2020.

The DS (NL) proposes to classify the substance as Skin Sens. 1B; H317, Repr. 2; H361d and to add M-factors for the aquatic hazards (Aquatic Acute 1; H400 (M=100), Aquatic Chronic 1; H410 (M=10)).

Skin sensitisation, reproductive toxicity and hazards to the aquatic environment were open for comments during the Consultation. An *ad hoc* consultation was carried out on the two new LLNA studies.

RAC adopted by consensus the opinion with a proposal for the harmonised classification and labelling as indicated in Table 1 below.

Rapporteurs to revise the opinion in accordance with the discussion in RAC and to provide it to SECR.

<p>[Repr. 2; H361d, Aquatic Acute 1; H400 (M=100), Aquatic Chronic 1; H410 (M=10)]</p> <p>RAC agreed on no classification for skin sensitisation, fertility and for effects on or via lactation.</p>	<p>SECR to make an editorial check of the opinion documents in consultation with the Rapporteurs.</p> <p>SECR to forward the adopted opinion and its annexes to COM and publish it on the ECHA website.</p>
<p>The expert accompanying the ECPA Stakeholder Observer commented on developmental toxicity.</p>	
<p>9. Pyridalyl (ISO)</p>	
<p>The Chair welcomed the Dossier Submitter representative and informed that pyridalyl (ISO) is an active substance used in plant protection products as an insecticide. It has no existing entry in Annex VI to the CLP Regulation. The legal deadline for the adoption of an opinion was 31 July 2020.</p> <p>The DS (NL) proposes to classify the substance as Skin Sens. 1; H317, Repr. 2; H361d, Aquatic Acute 1; H400 (M=1000) and Aquatic Chronic 1; H410 (M=100).</p> <p>Selected physical hazards (explosive, flammable liquid, self-reactive substance or mixture, pyrophoric liquid, substance or mixture which in contact with water emits flammable gas, oxidising liquid), acute toxicity, skin corrosion/irritation, serious eye damage/eye irritation, skin sensitisation, germ cell mutagenicity, carcinogenicity, reproductive toxicity, STOT SE, STOT RE and hazards to the aquatic environment were open for comments during the Consultation.</p>	
<p>RAC adopted <u>by consensus</u> the opinion with a proposal for the harmonised classification and labelling as indicated in Table 1 below.</p> <p>[Skin Sens. 1; H317, Aquatic Acute 1; H400 (M=1000), Aquatic Chronic 1; H410 (M=100)]</p> <p>RAC agreed on no classification for physical hazards, acute toxicity, skin corrosion/irritation, serious eye damage/eye irritation, germ cell mutagenicity, carcinogenicity, STOT SE, STOT RE, fertility (due to inconclusive data), development and for effects on or via lactation.</p>	<p>Rapporteurs to revise the opinion in accordance with the discussion in RAC and to provide it to SECR.</p> <p>SECR to make an editorial check of the opinion documents in consultation with the Rapporteurs.</p> <p>SECR to forward the adopted opinion and its annexes to COM and publish it on the ECHA website.</p>
<p>10. Methyl methacrylate</p>	
<p>The Chair welcomed the Dossier Submitter representative, two Occasional Stakeholder Observers, the expert accompanying the Cefic Regular Stakeholder Observer and the expert accompanying the EUPC Occasional Stakeholder Observer. He informed that methyl methacrylate is an industrial chemical with several uses including as an adhesive and sealant, as a monomer for polymerisation or intermediate in synthesis of other chemicals, manufacturing of acrylic sheets, in the manufacture of resins. The substance has an existing entry in Annex VI as Flam. Liq. 2; H225, Skin Irrit. 2; H315, Skin Sens. 1; H317, STOT SE 3; H335 and note D. The legal deadline for the adoption of an opinion was 29 August 2020.</p>	

The DS (FR) proposes to add classification for respiratory sensitisation (Resp. Sens. 1; H334).

Respiratory sensitisation was the only hazard class open for comments during the Consultation.

RAC adopted by consensus the opinion with a proposal for the harmonised classification and labelling as indicated in Table 1 below.

[Resp. Sens. 1; H334]

Rapporteurs to revise the opinion in accordance with the discussion in RAC and to provide it to SECR.

SECR to make an editorial check of the opinion documents in consultation with the Rapporteurs.

SECR to forward the adopted opinion and its annexes to COM and publish it on the ECHA website.

The expert accompanying the Cefic Stakeholder Observer and the expert accompanying the Ectoc Occasional Stakeholder Observer commented on respiratory sensitisation.

7. Minutes of RAC-52B-2

- a) Table with Summary Record of the Proceedings, and Conclusions and Action points from RAC-52B Part 2

Table 1: CLH opinions which were adopted at RAC-52B Part 2

1. Pyridalyl (ISO)

2. 2,4,6-tri-tert-butylphenol

3. Pendimethalin (ISO)

4. Ammonium bromide

5. Methyl methacrylate

6. Sodium pyrithione

7. 2-(2-methoxyethoxy)ethanol

8. Isoflucypram

9. Bisphenol A

10. Dimoxystrobin (ISO)

Table 1

1. Pyridalyl (ISO)

Classification and labelling in accordance with the CLP Regulation (Regulation (EC) 1272/2008)

	Index No	International Chemical Identification	EC No	CAS No	Classification		Labelling			Specific Conc. Limits, M-factors and ATE	Notes
					Hazard Class and Category Code(s)	Hazard statement Code(s)	Pictogram, Signal Word Code(s)	Hazard statement Code(s)	Suppl. Hazard statement Code(s)		
Current Annex VI entry	No current Annex VI entry										
Dossier submitters proposal	613-RST-VW-Y	pyridalyl (ISO); 2,6-dichloro-4-(3,3-dichloroallyloxy)phenyl 3-[5-(trifluoromethyl)-2-pyridyloxy]propyl ether	-	179101-81-6	Repr. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H361d H317 H400 H410	GHS08 GHS07 GHS09 Wng	H361d H317 H410		M=1000 M=100	
RAC opinion	613-RST-VW-Y	pyridalyl (ISO); 2,6-dichloro-4-(3,3-dichloroallyloxy)phenyl 3-[5-(trifluoromethyl)-2-pyridyloxy]propyl ether	-	179101-81-6	Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H317 H400 H410	GHS07 GHS09 Wng	H317 H410		M=1000 M=100	
Resulting entry in Annex VI if adopted by RAC and agreed by Commission	613-RST-VW-Y	pyridalyl (ISO); 2,6-dichloro-4-(3,3-dichloroallyloxy)phenyl 3-[5-(trifluoromethyl)-2-pyridyloxy]propyl ether	-	179101-81-6	Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H317 H400 H410	GHS07 GHS09 Wng	H317 H410		M=1000 M=100	

2. 2,4,6-tri-tert-butylphenol

Classification and labelling in accordance with the CLP Regulation (Regulation (EC) 1272/2008)

	Index No	Chemical name	EC No	CAS No	Classification		Labelling			Specific Conc. Limits, M-factors and ATE	Notes
					Hazard Class and Category Code(s)	Hazard statement Code(s)	Pictogram, Signal Word Code(s)	Hazard statement Code(s)	Suppl. Hazard statement Code(s)		
Current Annex VI entry					No current Annex VI entry						
Dossier submitters proposal	TBD	2,4,6-tri-tert-butylphenol	211-989-5	732-26-3	Repr. 2 Acute Tox. 4 STOT RE 1 Skin Sens. 1B	H361d H302 H372 (liver) H317	GHS08 GHS07 Dgr	H361d H302 H372 H317		oral: ATE = 500 mg/kg bw	
RAC opinion	TBD	2,4,6-tri-tert-butylphenol	211-989-5	732-26-3	Repr. 1B Acute Tox. 4 STOT RE 2 Skin Sens. 1B	H360D H302 H373 (liver) H317	GHS08 GHS07 Dgr	H360D H302 H373 (liver) H317		oral: ATE = 500 mg/kg bw	
Resulting Annex VI entry if agreed by COM	TBD	2,4,6-tri-tert-butylphenol	211-989-5	732-26-3	Repr. 1B Acute Tox. 4 STOT RE 2 Skin Sens. 1B	H360D H302 H373 (liver) H317	GHS08 GHS07 Dgr	H360D H302 H373 (liver) H317		oral: ATE = 500 mg/kg bw	

3. Pendimethalin (ISO)

Classification and labelling in accordance with the CLP Regulation (Regulation (EC) 1272/2008)

	Index No	Chemical name	EC No	CAS No	Classification		Labelling			Specific Conc. Limits, M-factors and ATE	Notes
					Hazard Class and Category Code(s)	Hazard statement Code(s)	Pictogram, Signal Word Code(s)	Hazard statement Code(s)	Suppl. Hazard statement Code(s)		
Current Annex VI entry	609-042-00-X	pendimethalin (ISO); <i>N</i> -(1-ethylpropyl)-2,6-dinitro-3,4-xylidene	254-938-2	40487-42-1	Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H317 H400 H410	GHS07 GHS09 Wng	H317 H410			
Dossier submitters proposal	609-042-00-X	pendimethalin (ISO); <i>N</i> -(1-ethylpropyl)-2,6-dinitro-3,4-xylidene	254-938-2	40487-42-1	Retain Aquatic Acute 1 Aquatic Chronic 1 Add Repr. 2 Modify Skin Sens. 1B	Retain H317 H400 H410 Add H361d	Retain GHS07 GHS09 Wng Add GHS08	Retain H317 H410 Add H361d		Add M=100 M=10	
RAC opinion	609-042-00-X	pendimethalin (ISO); <i>N</i> -(1-ethylpropyl)-2,6-dinitro-3,4-xylidene	254-938-2	40487-42-1	Retain Aquatic Acute 1 Aquatic Chronic 1 Add Repr. 2 Remove Skin Sens. 1	Retain H400 H410 Add H361d Remove H317	Retain GSH09 Wng Add GHS08 Remove GHS07	Retain H410 Add H361d Remove H317		Add M=100 M=10	
Resulting Annex VI entry agreed by COM	609-042-00-X	pendimethalin (ISO); <i>N</i> -(1-ethylpropyl)-2,6-dinitro-3,4-xylidene	254-938-2	40487-42-1	Repr. 2 Aquatic Acute 1 Aquatic Chronic 1	H361d H400 H410	GHS08 GSH09 Wng	H361d H410		M=100 M=10	

4. Ammonium bromide

Classification and labelling in accordance with the CLP Regulation (Regulation (EC) 1272/2008)

	Index No	Chemical name	EC No	CAS No	Classification		Labelling			Specific Conc. Limits, M-factors and ATE	Notes
					Hazard Class and Category Code(s)	Hazard statement Code(s)	Pictogram, Signal Word Code(s)	Hazard statement Code(s)	Suppl. Hazard statement Code(s)		
Current Annex VI entry	No current Annex VI entry										
Dossier submitters proposal	TBD	Ammonium bromide	235-183-8	12124-97-9	Repr. 1B Lact. STOT SE 3 STOT RE 2 Eye Irrit. 2	H360FD H362 H336 H373 (nervous system, thyroid) H319	GHS08 GHS07 Dgr	H360FD H362 H336 H373 (nervous system, thyroid) H319			
RAC opinion	TBD	Ammonium bromide	235-183-8	12124-97-9	Repr. 1B Lact. STOT SE 3 STOT RE 1 Eye Irrit. 2	H360FD H362 H336 H372 (nervous system) H319	GHS08 GHS07 Dgr	H360FD H362 H336 H372 (nervous system) H319			
Resulting Annex VI entry if agreed by COM	TBD	Ammonium bromide	235-183-8	12124-97-9	Repr. 1B Lact. STOT SE 3 STOT RE 1 Eye Irrit. 2	H360FD H362 H336 H372 (nervous system) H319	GHS08 GHS07 Dgr	H360FD H362 H336 H372 (nervous system) H319			

5. Methyl methacrylate

Classification and labelling in accordance with the CLP Regulation (Regulation (EC) 1272/2008)

	Index No	Chemical name	EC No	CAS No	Classification		Labelling			Specific Conc. Limits, M-factors and ATE	Notes
					Hazard Class and Category Code(s)	Hazard statement Code(s)	Pictogram, Signal Word Code(s)	Hazard statement Code(s)	Suppl. Hazard statement Code(s)		
Current Annex VI entry	607-035-00-6	methyl methacrylate methyl 2-methylprop-2-enoate methyl 2-methylpropenoate	201-297-1	80-62-6	Flam. Liq. 2 STOT SE 3 Skin Irrit. 2 Skin Sens. 1	H225 H335 H315 H317	GHS02 GHS07 Dgr	H225 H335 H315 H317			D
Dossier submitters proposal	607-035-00-6	methyl methacrylate methyl 2-methylprop-2-enoate methyl 2-methylpropenoate	201-297-1	80-62-6	Add Resp. Sens. 1	Add H334	Add GHS08	Add H334			
RAC opinion	607-035-00-6	methyl methacrylate methyl 2-methylprop-2-enoate methyl 2-methylpropenoate	201-297-1	80-62-6	Add Resp. Sens. 1	Add H334	Add GHS08	Add H334			
Resulting Annex VI entry if agreed by COM	607-035-00-6	methyl methacrylate methyl 2-methylprop-2-enoate methyl 2-methylpropenoate	201-297-1	80-62-6	Flam. Liq. 2 STOT SE 3 Skin Irrit. 2 Resp. Sens. 1 Skin Sens. 1	H225 H335 H315 H334 H317	GHS02 GHS07 GHS08 Dgr	H225 H335 H315 H334 H317			D

6. Sodium pyrrithione

Classification and labelling in accordance with the CLP Regulation (Regulation (EC) 1272/2008)

	Index No	Chemical name	EC No	CAS No	Classification		Labelling			Specific Limits, and ATE	Conc. M-factors	Notes
					Hazard Class and Category Code(s)	Hazard statement Code(s)	Pictogram, Signal Word Code(s)	Hazard statement Code(s)	Suppl. Hazard statement Code(s)			
Current Annex VI entry												No current Annex VI entry
Dossier submitters proposal	TBD	Pyridine-2-thiol oxide, sodium salt	1-223-296-5	3811-73-2	Acute Tox. 3 Acute Tox. 4 Acute Tox. 4 STOT RE 1 Skin Irrit. 2 Eye Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 2	H331 H312 H302 H372 (mortality, neuromuscular system) H315 H319 H317 H400 H411	GHS06 GHS08 GHS09 Dgr	H331 H312 H302 H372 (mortality, neuromuscular system) H315 H319 H317 H410	EUH070	inhalation: ATE = 0.5mg/L (dusts or mists) dermal: ATE = 1800 mg/kg bw oral: ATE = 500 mg/kg bw M=100		
RAC opinion	TBD	Pyridine-2-thiol oxide, sodium salt	1-223-296-5	3811-73-2	Acute Tox. 3 Acute Tox. 3 Acute Tox. 4 STOT RE 1 Skin Irrit. 2 Eye Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 2	H331 H311 H302 H372 (nervous system) H315 H319 H317 H400 H411	GHS06 GHS07 GHS08 GHS09 Dgr	H331 H311 H302 H372 (nervous system) H315 H319 H317 H410	EUH070	inhalation: ATE = 0.5mg/L (dusts or mists) dermal: ATE = 790 mg/kg bw oral: ATE = 500 mg/kg bw M=100		
Resulting Annex VI entry if agreed by COM	TBD	Pyridine-2-thiol oxide, sodium salt	1-223-296-5	3811-73-2	Acute Tox. 3 Acute Tox. 3 Acute Tox. 4 STOT RE 1 Skin Irrit. 2 Eye Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 2	H331 H311 H302 H372 (nervous system) H315 H319 H317 H400 H411	GHS06 GHS07 GHS08 GHS09 Dgr	H331 H311 H302 H372 (nervous system) H315 H319 H317 H410	EUH070	inhalation: ATE = 0.5mg/L (dusts or mists) dermal: ATE = 790 mg/kg bw oral: ATE = 500 mg/kg bw M=100		

7.2-(2-methoxyethoxy)ethanol

Classification and labelling in accordance with the CLP Regulation (Regulation (EC) 1272/2008)

	Index No	Chemical name	EC No	CAS No	Classification		Labelling			Specific Conc. Limits, M-factors and ATE	Notes
					Hazard Class and Category Code(s)	Hazard statement Code(s)	Pictogram, Signal Word Code(s)	Hazard statement Code(s)	Suppl. Hazard statement Code(s)		
Current Annex VI entry	603-107-00-6	2-(2-methoxyethoxy)ethanol	203-906-6	111-77-3; (155232 3-12-2)	Repr. 2	H361d***	GHS08 Wng	H361d***			
Dossier submitters proposal	603-107-00-6	2-(2-methoxyethoxy)ethanol	203-906-6	111-77-3; (155232 3-12-2)	Modify Repr. 1B	Modify H360D	Retain GHS08 Modify Dgr	Modify H360D			
RAC opinion	603-107-00-6	2-(2-methoxyethoxy)ethanol	203-906-6	111-77-3; (155232 3-12-2)	Modify Repr. 1B	Modify H360D	Retain GHS08 Modify Dgr	Modify H360D		Repr. 1B; H360D: C ≥ 3 %	
Resulting Annex VI entry if agreed by COM	603-107-00-6	2-(2-methoxyethoxy)ethanol	203-906-6	111-77-3; (155232 3-12-2)	Repr. 1B	H360D	GHS08 Dgr	H360D		Repr. 1B; H360D: C ≥ 3 %	

8. Isoflucypram

Classification and labelling in accordance with the CLP Regulation (Regulation (EC) 1272/2008)

	Index No	Chemical name	EC No	CAS No	Classification		Labelling			Specific Conc. Limits, M-factors and ATE	Notes
					Hazard Class and Category Code(s)	Hazard statement Code(s)	Pictogram, Signal Word Code(s)	Hazard statement Code(s)	Suppl. Hazard statement Code(s)		
Current Annex VI entry	No current Annex VI entry										
Dossier submitters proposal	TBD	N-(5-chloro-2-isopropylbenzyl)-N-cyclopropyl-3-(difluoromethyl)-5-fluoro-1-methyl-1H-pyrazole-4-carboxamide; isoflucypram	n/a	1255734-28-1	Acute Tox. 4 Skin Sens. 1B Aquatic Acute 1 Aquatic Chronic 1	H332 H317 H400 H410	GHS07 GHS09 Wng	H332 H317 H410		inhalation: ATE = 2.2 mg/L M=10 M=1	
RAC opinion	TBD	N-(5-chloro-2-isopropylbenzyl)-N-cyclopropyl-3-(difluoromethyl)-5-fluoro-1-methyl-1H-pyrazole-4-carboxamide; isoflucypram	n/a	1255734-28-1	Repr. 2 Acute Tox. 4 Skin Sens. 1B Aquatic Acute 1 Aquatic Chronic 1	H361f H332 H317 H400 H410	GHS08 GHS07 GHS09 Wng	H332 H317 H410		inhalation: ATE = 2.2 mg/L (dusts or mists) M=10 M=1	
Resulting Annex VI entry if agreed by COM	TBD	N-(5-chloro-2-isopropylbenzyl)-N-cyclopropyl-3-(difluoromethyl)-5-fluoro-1-methyl-1H-pyrazole-4-carboxamide; isoflucypram	n/a	1255734-28-1	Repr. 2 Acute Tox. 4 Skin Sens. 1B Aquatic Acute 1 Aquatic Chronic 1	H361f H332 H317 H400 H410	GHS08 GHS07 GHS09 Wng	H332 H317 H410		inhalation: ATE = 2.2 mg/L (dusts or mists) M=10 M=1	

9. Bisphenol A

Classification and labelling in accordance with the CLP Regulation (Regulation (EC) 1272/2008)

	Index No	Chemical name	EC No	CAS No	Classification		Labelling			Specific Conc. Limits, M-factors and ATE	Notes
					Hazard Class and Category Code(s)	Hazard statement Code(s)	Pictogram, Signal Word Code(s)	Hazard statement Code(s)	Suppl. Hazard statement Code(s)		
Current Annex VI entry	604-030-00-0	4,4'-isopropylidenediphenol; bisphenol A	201-245-8	80-05-7	Repr. 1B STOT SE 3 Eye Dam. 1 Skin Sens. 1	H360F H335 H318 H317	GHS08 GHS07 GHS05 Dgr	H360F H335 H318 H317			
Dossier submitters proposal	604-030-00-0	4,4'-isopropylidenediphenol; bisphenol A	201-245-8	80-05-7	Retain Repr. 1B STOT SE 3 Eye Dam. 1 Skin Sens. 1 Add Aquatic Acute 1 Aquatic Chronic 1	Retain H360F H335 H318 H317 Add H400 H410	Retain GHS08 GHS07 GHS05 Dgr Add GHS09	Retain H360F H335 H318 H317 Add H410		Add M=1 M=10	
RAC opinion	604-030-00-0	4,4'-isopropylidenediphenol; bisphenol A	201-245-8	80-05-7	Retain Repr. 1B STOT SE 3 Eye Dam. 1 Skin Sens. 1 Add Aquatic Acute 1 Aquatic Chronic 1	Retain H360F H335 H318 H317 Add H400 H410	Retain GHS08 GHS07 GHS05 Dgr Add GHS09	Retain H360F H335 H318 H317 Add H410		Add M=1 M=10	
Resulting Annex VI entry if agreed by COM	604-030-00-0	4,4'-isopropylidenediphenol; bisphenol A	201-245-8	80-05-7	Repr. 1B STOT SE 3 Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H360F H335 H318 H317 H400 H410	GHS08 GHS07 GHS05 GHS09 Dgr	H360F H335 H318 H317 H410		M=1 M=10	

10. Dimoxystrobin (ISO)

Classification and labelling in accordance with the CLP Regulation (Regulation (EC) 1272/2008)

	Index No	Chemical name	EC No	CAS No	Classification		Labelling			Specific Conc. Limits, M-factors and ATE	Notes	
					Hazard Class and Category Code(s)	Hazard statement Code(s)	Pictogram, Signal Code(s)	Word	Hazard statement Code(s)			Suppl. Hazard statement Code(s)
Current Annex VI entry	616-164-00-7	dimoxystrobin (ISO); (2E)-2-{2-[(2,5-dimethylphenoxy)methyl]phenyl}-2-(methoxyimino)-N-methylacetamide; (E)-2-(methoxyimino)-N-methyl-2-[α -(2,5-xylyloxy)-o-tolyl]acetamide		149961-52-4	Carc. 2 Repr. 2 Acute Tox. 4* Aquatic Acute 1 Aquatic Chronic 1	H351 H361d*** H332 H400 H410	GHS08 GHS07 GHS09 Wng		H351 H361d*** H332 H410			
Dossier submitters proposal	616-164-00-7	dimoxystrobin (ISO); (2E)-2-{2-[(2,5-dimethylphenoxy)methyl]phenyl}-2-(methoxyimino)-N-methylacetamide; (E)-2-(methoxyimino)-N-methyl-2-[α -(2,5-xylyloxy)-o-tolyl]acetamide		149961-52-4	Remove: Repr. 2 Add: Lact. STOT RE 2 Modify: Acute Tox. 4 Retain: Aquatic Acute 1 Aquatic Chronic 1	Remove: H361d*** Add: H362 H373 (blood) Retain: H332 H400 H410	Retain: GHS08 GHS07 GHS09 Wng	Remove: H361d*** Add: H362 H373 (blood) Retain: H332 H410		Add: inhalation: ATE = 1.3 mg/L (dusts or mists) M=100 M=100		
RAC opinion	616-164-00-7	dimoxystrobin (ISO); (2E)-2-{2-[(2,5-dimethylphenoxy)methyl]phenyl}-2-(methoxyimino)-N-methylacetamide; (E)-2-(methoxyimino)-N-methyl-2-[α -(2,5-xylyloxy)-o-tolyl]acetamide		149961-52-4	Repr. 2 Acute Tox. 4 Aquatic Acute 1 Aquatic Chronic 1	H361d H332 H400 H410	GHS08 GHS07 GHS09 Wng		H361d H332 H410		inhalation: ATE = 1.3 mg/L (dusts or mists) M=100 M=100	
Resulting Annex VI entry if agreed by COM	616-164-00-7	dimoxystrobin (ISO); (2E)-2-{2-[(2,5-dimethylphenoxy)methyl]phenyl}-2-(methoxyimino)-N-methylacetamide; (E)-2-(methoxyimino)-N-methyl-2-[α -(2,5-xylyloxy)-o-tolyl]acetamide			Carc. 2 Repr. 2 Acute Tox. 4 Aquatic Acute 1 Aquatic Chronic 1	H351 H361d H332 H400 H410	GHS08 GHS07 GHS09 Wng		H351 H361d H332 H410		inhalation: ATE = 1.3 mg/L (dusts or mists) M=100 M=100	

Part III. List of Attendees of the RAC-52B-2 meeting

<u>RAC Members</u>	Santonen Tiina
Barański Bogusław	Schlüter Urs
Biró Anna	Schulte Agnes
Bjørge Christine	Schuur Gerlienke
Borg Daniel	Sørensen Hammer Peter
Carvalho João	Sogorb Miguel A.
de la Flor Tejero Ignacio	Spetseris Nikolaos
Doak Malcolm	Stahlmann Ralf
Docea Anca Oana	Tobiassen Lea Stine
Dobrev Ivan	Tsitsimpikou Christina
Geoffroy Laure	Užomeckas Žilvinas
Hakkert Betty	Varnai Veda
Husa Stine	
Kadiķis Normunds	<u>Apologies, Members</u>
Kapelari Sonja	Aquilina Gabriele
Karadjova Irina	Brovkina Julija
Leinonen Riitta	Chankova-Petrova Stephka
Losert Annemarie	Xanthos Theodore
Lund Bert-Ove	Zeljezic Davor
Martínek Michal	
Menard Srpčič Anja	
Moeller Ruth	
Moldov Raili	
Murray Brendan	
Neumann Michael	
Paris Pietro	
Peczowska Beata	
Pribu Mihaela	
Printemps Nathalie	
Rucki Marian	

<u>Members' advisers</u>
Hoffmann Frauke (Agnes Schulte)
Mahiout Selma (Tiina Santonen)
Martin Theresa (Ralf Stahlmann)
Saksa Jana (Raili Moldov)
Sonnenburg Anna (Ralf Stahlmann)
Suutari Tiina (Riitta Leinonen)
<u>Invited experts</u>
Catone Tiziana (Adviser to G. Aquilina)
Facchin Manuel (Adviser to A. Losert)
Rodriguez Wendy (incoming RAC member)
Russo Maria Teresa (Adviser to G. Aquilina)
<u>Dossier submitters</u>
Charles Sandrine (methyl methacrylate)
Geraets Lisbeth (pyridalyl)
Groothuis Floris (DEGME, pendimethalin)
Henriksson Witas Erika (Ammonium bromide)
Kaßner Franziska (Bisphenol A)
Staude Claudia (Bisphenol A)
<u>Regular stakeholder observers</u>
De BakerLiisi (Cefic)
Robinson Jan (AISE)

Ruelens Paul (ECPA)
Verougstraete Violaine (Eurometaux)
<u>Occasional stakeholders</u>
Cassart Michel (Plastics Europe)_ Bisphenol A
de Matos Olivier (ECETOC)_ Ammonium bromide; Bisphenol A; Methyl methacrylate
Perfetti Marco (EUPC)_ Bisphenol A, Methyl methacrylate
Suarez Merino Blanca (Nanotechnology Industries Association) Ammonium bromide, 2,4,6-tri-tert-butylphenol, Bisphenol A
<u>Stakeholder experts</u>
Gelbke Heinz-Peter (Cefic/GMX)_methyl methacrylate
Gestermann Sven (Plastics Europe/ PC/BPA group of PlasticsEurope)_ Bisphenol A
Jacobi Sylvia (Cefic/BSEF_International Bromine Council)_ Ammonium bromide
Kelsey Jeff (Cefic/Chamsage Ltd)_diethylene glycol monomethyl ether
Melching-Kollmus Stephanie (ECPA/BASF)_ dimoxystrobin (ISO)
Moore Nigel (Cefic/Lonza AG)_Sodium pyrithione
Pemberton Mark (ECETOC/Systox Ltd)_methyl methacrylate
Stollhofer Germaine (ECPA/Thor)_Sodium pyrithione
Tesh Sheila (ECPA/Tesh Consultants for BASF)_Pendimethalin (ISO)
Tinwell Helen (ECPA/Bayer CropScience)_ Isoflucypram
Wölz Jan (CEFIC/ Cefic BPA member)_ Bisphenol A
<u>Commission</u>
Kilian Karin (DG ENV)

Part II. LIST OF ANNEXES

ANNEX I Final Agenda of the RAC-52B-2 meeting

ANNEX II List of documents submitted to the Members of the Committee for Risk Assessment for the RAC-52B-2 meeting

ANNEX III Declarations of conflicts of interest to the Agenda of the RAC-52B-2 meeting

Final Agenda
52nd meeting of the Committee for Risk Assessment
CLH plenary - *Part 2*

6 - 8 October 2020

Tuesday 6 October starts at 14.00
Thursday 8 October ends at 17.30

Virtual meeting

Item 1 – Welcome and Apologies

Item 2 – Adoption of the Agenda

RAC/A/52B-2/2020
For adoption

Item 3 – Declarations of conflicts of interest to the Agenda

Item 4 – Appointment of (co-)rapporteurs

a) Appointment of (co-)rapporteurs for CLH dossiers

For agreement

Item 5 – Harmonised classification and labelling (CLH)

5.1 CLH dossiers

A. Hazard classes for agreement without plenary debate (fast-track)

- Isoflucypram: physical hazards, acute toxicity, STOT SE, skin corrosion/ irritation, serious eye damage/eye irritation, respiratory and skin sensitisation, germ cell mutagenicity, aspiration hazards, hazards to the aquatic environment

- Ammonium bromide: acute toxicity (dermal and oral), STOT SE, serious eye damage/eye irritation, skin corrosion/irritation, skin sensitisation, germ cell mutagenicity, carcinogenicity
- Dimoxystrobin (ISO): acute toxicity, skin corrosion/irritation, serious eye damage/eye irritation, skin sensitisation, hazards to the aquatic environment
- 2,4,6-tri-tert-butylphenol: acute toxicity (oral, dermal), skin corrosion/irritation, serious eye damage/eye irritation, skin sensitisation, germ cell mutagenicity, carcinogenicity, STOT SE
- Sodium pyrithione: physical hazards, skin corrosion/irritation, serious eye damage/eye irritation, STOT SE, germ cell mutagenicity, carcinogenicity, hazards to the aquatic environment
- Pendimethalin (ISO): hazards to the aquatic environment
- Pyridalyl (ISO): physical hazards (except explosives and self-reactive substance), acute toxicity, skin corrosion/irritation, serious eye damage/eye irritation, skin sensitisation, germ cell mutagenicity, carcinogenicity, STOT RE, STOT SE, hazards to the aquatic environment

B. Hazard classes for agreement with plenary debate

- 1) Isoflucypram (EC: -; CAS: 1255734-28-1)
- 2) ammonium bromide (EC: 235-183-8; CAS: 80-62-6)
- 3) dimoxystrobin (ISO) (EC: -; CAS: 149961-52-4)
- 4) diethylene glycol monomethyl ether (EC: 203-906-6; CAS: 111-77-3)
- 5) 2,4,6-tri-tert-butylphenol (EC: 211-989-5; CAS: 732-26-3)
- 6) sodium pyrithione (EC: 223-296-5; CAS: 3811-73-2)
- 7) bisphenol A (EC: 201-245-8; CAS: 80-05-7)
- 8) pendimethalin (ISO) (EC: 254-938-2; CAS: 40487-42-1)
- 9) pyridalyl (ISO) (EC: -; CAS: 179101-81-6)
- 10) methyl methacrylate (EC2-6): 201-297-1; CAS: 80-62-6)

For discussion and adoption

Item 6 – AOB

Report by the RAC Member on the first meeting of the REACH and CLP Competent Authorities Sub-Group on Bioelution

For information

Item 7 – Minutes of RAC-52B-2

Table with Summary Record of the Proceedings, and Conclusions and Action points from RAC-52B Part 2.

For adoption

Annex II (RAC 52B-2)

Documents submitted to the Members of the Committee for Risk Assessment for the RAC 52B-2 meeting.

Document number	Title
RAC/A/52B-2/2020	Final Draft Agenda

ANNEX III (RAC-52B_Part2)

The following participants, including those for whom the Chairman declared the interest on their behalf, declared potential conflicts of interest with the Agenda items (according to Art 9 (2) of RAC RoPs)

Dossier / DS	RAC Member	Reason for potential CoI / Working for
NEW DOSSIERS		
1) Bisphenol A DE	Agnes SCHULTE	Working for the CA submitting the dossier; asked to refrain from voting in the event of a vote on this substance - no other mitigation measures applied. No personal involvement.
	Urs SCHLUTER	Working for the CA submitting the dossier; asked to refrain from voting in the event of a vote on this substance - no other mitigation measures applied. No personal involvement.
	Michael NEUMANN	Working for the CA submitting the dossier; asked to refrain from voting in the event of a vote on this substance - no other mitigation measures applied. No personal involvement.
	Ivan DOBREV	Working for the CA submitting the dossier; asked to refrain from voting in the event of a vote on this substance - no other mitigation measures applied. No personal involvement.
1) Pyridalyl (ISO) 2) Pendimethalin (ISO) 3) diethylene glycol monomethyl ether (2-(2-methoxyethoxy ethanol)) NL	Betty HAKKERT	Working for the CA submitting the dossier; asked to refrain from voting in the event of a vote on this substance - no other mitigation measures applied. No personal involvement.
	Gerlienke SCHUUR	Working for the CA submitting the dossier; asked to refrain from voting in the event of a vote on this substance - no other mitigation measures applied. No personal involvement.

Dossier / DS	RAC Member	Reason for potential CoI / Working for
NEW DOSSIERS		
2,4,6-tri tert-butylphenol BE	Julie SEBA + Wendy Rodriguez (adviser)	Working for the CA submitting the dossier; asked to refrain from voting in the event of a vote on this substance - no other mitigation measures applied. No personal involvement.
1) Sodium pyrithione 2) Ammonium bromide SE	Bert-Ove LUND	Working for the CA submitting the dossier; asked to refrain from voting in the event of a vote on this substance - no other mitigation measures applied. No personal involvement.
	Daniel BORG	Working for the CA submitting the dossier; asked to refrain from voting in the event of a vote on this substance - no other mitigation measures applied. No personal involvement.
Dimoxystrobin (ISO) HU	Anna BIRO	Working for the CA submitting the dossier; asked to refrain from voting in the event of a vote on this substance - no other mitigation measures applied. No personal involvement.
Methyl methacrylate FR	Nathalie PRINTEMPS	Working for the CA submitting the dossier; asked to refrain from voting in the event of a vote on this substance - no other mitigation measures applied. No personal involvement.
Isoflucypram NO	Christine BJORGE	Working for the CA submitting the dossier; asked to refrain from voting in the event of a vote on this substance - no other mitigation measures applied. No personal involvement.
	Stine HUSA	Working for the CA submitting the dossier; asked to refrain from voting in the event of a vote on this substance - no other mitigation measures applied. No personal involvement.